Neuroendocrine tumors are cancers that begin in specialized cells called neuroendocrine cells. These cells have traits similar to those of nerve cells and hormone-producing cells. Neuroendocrine ...

Peptide receptor radionuclide therapy (PRRT) with lutetium dotatate is a treatment for well-differentiated neuroendocrine tumors that the U.S. Food and Drug Administration approved in 2018, but ...

PRRT系统综述表明其对晚期pNETs的PFS有优势且耐受性良好，但OS改善未达统计显著性，需更多高质量RCT验证。 放射性核素治疗（PRRT）在管理胰腺神经内分泌肿瘤（pNETs）患者方面显示出良好的潜力。然而，与其他治疗选项相比，其相对疗效和安全性仍缺乏足够的 ...

Transaxial slices of baseline positron emission tomography (PET) and fused PET/magnetic resonance imaging (MRI; left) demonstrate a somatostatin receptor-expressing meningioma in the left cavernous ...

Retrospective analysis of Peptide Receptor Radionuclide Therapy (PRRT) in Japanese patients with unresectable neuroendocrine tumor. This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I ...

A simple blood draw can provide physicians with valuable information that can determine if peptide receptor radionuclide therapy (PRRT) is likely to be effective in a patient with neuroendocrine ...

Chemotherapy with capecitabine plus temozolomide (CAP-TEM) in patients with advanced neuroendocrine neoplasms (NENs): an Italian multicenter retrospective analysis. This is an ASCO Meeting Abstract ...

Neuroendocrine cancer (NETS – for neuroendocrine tumors) is a rare, deadly form of the disease that attacks the intestines, pancreas, lungs, stomach and other parts of the body. Treatment options are ...